NCT04065087View on ClinicalTrials.gov

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 22, 2019

Primary Completion Date

May 27, 2022

Study Completion Date

August 27, 2022

Conditions
Newly Diagnosed Glioblastoma
Interventions
BIOLOGICAL

GX-I7

Investigational drug

OTHER

Placebo

Placebo drug

Trial Locations (1)

Unknown

St. Vincent Hospital, Suwon

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT04065087 - Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter